Omeros Corporation
http://www.omeros.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Omeros Corporation
Finance Watch: Kronos Reveals Second Round Of Job Cuts In Five Months
Restructuring Edition: Kronos restructured and cut 19% of its workforce in November and now will cut 21% of its remaining jobs. Also, Gritstone cut 40% of its workforce after missing out on an expected external funding payment and Kineta implemented a 64% workforce reduction.
Finance Watch: Ascendis Spins Out Ophthalmology Firm Eyconis With $150m
Private Company Edition: Publicly held Ascendis outsourced its preclinical AMD program to private Eyconis. Also, Innovation Endeavors revealed a new $630m VC fund and Mirae raised $50m for its first life science fund, while Accent, Comanche and Tr1X each brought in $75m rounds.
Genentech Places Bet On Polymer Nanoparticle-Based Delivery With GenEdit Deal
Deal Snapshot: The Roche subsidiary will use GenEdit’s hydrophilic nanoparticles to develop genetic medicines for autoimmune diseases meant to overcome the limitations of existing delivery methods.
Omeros Crashes To All-Time Low On IgAN Failure
Development of narsoplimab in the kidney disease has been called off, making a forthcoming regulatory decision in a different use all the more important.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice